H S

Omrix Biopharma Is Sure To Bounce Following Pre-Market Selloff

As a side note, it is interesting to note that in a recent report from Citi, the analyst discussed Thrombin and compared it to King Pharmaceutical's Thrombin, BUT he ~forgot~ about ZGEN's rhThrombin that will likely to trump both.